In addition, CXCL9 and CXCL10 decreased in a patient’s nonCD8+ PBMCs (Figure 4I) but CXCL9 concentration increased in the sera of patients with lung cancer (Figure 4J). This evidence concerns the gene CXCL10 and lung carcinoma.